What Conditions Are Treated with Saphnelo Infusions?
Saphnelo (anifrolumab) infusions are a relatively new treatment approved for managing moderate to severe systemic lupus erythematosus (SLE) that has not responded adequately to other treatments. This biologic drug works by inhibiting the type I interferon receptor, thus reducing the overactive immune response that characterizes lupus. The treatment is specifically targeted at patients who suffer from a high disease activity despite standard therapy, aiming to reduce the frequency of flare-ups and control the progression of the disease.
Saphnelo has also shown potential in clinical trials for other autoimmune conditions involving similar pathways, though its primary approval and use remain focused on lupus. This medication represents a significant advancement in lupus management, providing an option for patients who have struggled with other treatments. It is generally administered in a clinical setting, allowing healthcare providers to monitor patients for any immediate reactions during and after the infusion process.
